


maternal country of birth, BMI, smoking in early pregnancy, educational level, and disposable income in the year before pregnancy.

**Results:** Women with SpA (n=1394) were found to be at increased risk of several adverse outcomes compared to general population comparators (n=13932), as displayed in the Figure 1. Women with SpA had an increased risk of gestational diabetes (adjusted RR 1.88 [95% CI 1.10; 2.56]), elective and emergency Cesarean delivery (adjusted RR 1.54 [95% CI 1.32; 1.79] and 1.23 [95% CI 1.02; 1.48], respectively), and moderately preterm birth (adjusted RR 1.52 [95% CI 1.18; 1.97]). An association was seen with both spontaneous and medically indicated preterm birth, but the increase was only significant for spontaneous preterm birth. The risk estimate for preeclampsia was also increased, but failed to reach significance (adjusted RR 1.32 [95% CI 0.96; 1.81]). Infants to mothers with SpA were not more likely to be born SGA, but there was a slightly increased risk estimate of infection during their first year of life (adjusted RR 1.23 [95% CI 0.98; 1.53]).



**Figure 1.** Number of events of adverse pregnancy outcomes among a nationwide cohort of births (n=1394) in Swedish women with SpA and comparator births (n=13932, matched 1:10 on birth year, maternal age, and parity). Relative risks from Poisson regression, adjusted for maternal country of birth, BMI, smoking in early pregnancy, educational level, and disposable income in the year before pregnancy.

**Conclusion:** While most pregnancies in women with SpA are uneventful, there is an increased risk for a number of adverse pregnancy outcomes. The increased risks for both emergency Cesarean delivery and spontaneous preterm birth suggest that these differences are not only driven by a different management of SpA pregnancies.

#### REFERENCES:

[1] Mokbel A, Lawson DO, Farrokhyar F. Pregnancy outcomes in women with ankylosing spondylitis: a scoping literature and methodological review. *Clinical Rheumatology* 2021;40(9):3465-80.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.292

OP0127

### UNFAVORABLE PREGNANCY OUTCOME IS SIGNIFICANTLY ASSOCIATED WITH CORTICOSTEROID EXPOSURE DURING PREGNANCY IN WOMEN WITH RHEUMATOID ARTHRITIS: ANALYSIS OF THE PROSPECTIVE GR2 COHORT

S. Hamroun<sup>1</sup>, M. Couderc<sup>2</sup>, R. M. Flipo<sup>3</sup>, L. Gossec<sup>4</sup>, C. Richez<sup>5</sup>, R. Belkhir<sup>6</sup>, A. Frazier-Mironer<sup>7</sup>, V. Devauchelle-Pensec<sup>8</sup>, H. Marotte<sup>9</sup>, J. Sellam<sup>10</sup>, E. Gervais<sup>11</sup>, A. Deroux<sup>12</sup>, C. Lukas<sup>13</sup>, E. Derris<sup>14</sup>, E. Chatelus<sup>15</sup>, N. Costedoat-Chalumeau<sup>16</sup>, A. Moltó on behalf of GR2 Group. <sup>1</sup>Cochin Hospital, Rheumatology, Paris, France; <sup>2</sup>CHU Gabriel-Montpied, Rheumatology, Clermont-Ferrand, France; <sup>3</sup>Chu De Lille, Rheumatology, Lille, France; <sup>4</sup>University Hospitals Pitié Salpêtrière - Charles Foix, Rheumatology, Paris, France; <sup>5</sup>Hospital Center University De Bordeaux, Rheumatology, Bordeaux, France; <sup>6</sup>Bicetre Hospital, Rheumatology, Le Kremlin-Bicêtre, France; <sup>7</sup>Lariboisière Hospital AP-HP, Rheumatology, Paris, France; <sup>8</sup>CHU Brest, Rheumatology, Brest, France; <sup>9</sup>University Hospital of Saint-Étienne, Rheumatology, Saint-Priest-en-Jarez, France; <sup>10</sup>Hospital Saint-Antoine Ap-Hp, Rheumatology, Paris, France; <sup>11</sup>Poitiers University Hospital, Rheumatology, Poitiers, France; <sup>12</sup>Chu Grenoble Alpes, Internal Medicine, La Tronche, France; <sup>13</sup>Hospital Center University De Montpellier, Rheumatology, Montpellier, France; <sup>14</sup>Hospital Center- Le Mans, Rheumatology, Le Mans, France; <sup>15</sup>CHRU Strasbourg, Rheumatology, Strasbourg, France; <sup>16</sup>Cochin Hospital, Internal Medicine, Paris, France

**Background:** Rheumatoid arthritis (RA) is one of the most common chronic inflammatory diseases and regularly affects women of childbearing age<sup>1</sup>. However, there is limited knowledge about the impact of the disease and its treatment on pregnancy.

**Objectives:** The aim of the study was to determine the factors associated with adverse pregnancy outcome in women with RA.

**Methods:** All RA patients (diagnosis according to the Rheumatologist) included in the national multicenter GR2 cohort from 2015 to June 2021 were included in the analysis. Patients could be included either with a pregnancy wish (i.e., pre-conceptional period) or because of a clinical pregnancy (<12 weeks of gestation). The main endpoint was favorable pregnancy outcome, a composite outcome defined as a live birth at term  $\geq 37$  gestation weeks of a healthy newborn with a weight greater than the 10th percentile. Disease activity was defined by a DAS28-CRP score  $> 3.2$  at least once during pregnancy. We performed a multilevel logistic regression model, in which we considered patient and center random effects (patient random effect for some women included in the cohort two times). We used a multiple imputation procedure to address missing data among the explanatory variables. Results are presented as an odds ratio (OR) with confidence interval (CI).

**Results:** Among the 167 pregnancies in women with RA included in the GR2 cohort, 92 were retained for analysis of obstetrical outcome. Of these, 43 (46.2%), 8 (7.9%), 40 (43.5%) were exposed to corticosteroid, NSAID and biologics at least once during pregnancy, respectively. A moderate or severe disease activity at least once during pregnancy was found in 20 (21.8%) pregnancies. A live birth was found in 83 (90.2%) women, including 69 (83.1%) full-term births. Early miscarriages were observed in 9 (0.1%) women. A caesarean section was performed in 22 (23.9%) cases.

A favorable pregnancy outcome was found in 52 (56.5%) of the women. Unfavorable pregnancy outcome was mainly due to prematurity and small for gestational age, observed in 14 (16.9%) and 17 (20.5%), respectively. The multivariate model adjusted for age, BMI, nulliparity, active disease during pregnancy, smoking, and exposure to biologics and corticosteroids during pregnancy found an association between an unfavorable pregnancy outcome and nulliparity (OR 6.2 95% CI [2.1-17.8] p = 0.002), age (OR (per year) 1.1 95% CI [1.0-1.3] p = 0.02) and exposure to corticosteroids during pregnancy (OR 3.2 95% CI [1.1-9.6] p = 0.04).

**Conclusion:** This study provides original results on pregnancy in women with RA. It found a favorable pregnancy outcome in 56.5% of women. Unfavorable pregnancy outcome was associated with age, nulliparity and corticosteroids use during pregnancy, which argues for their careful use during pregnancy.

#### REFERENCES:

[1] Van den Brandt S. *Arthritis Res Ther.* 2017;19(1):64.

**Table 1. Multilevel logistic regression model: factors associated with unfavorable pregnancy outcome in women with RA.**

	Univariate analyses		Multivariate analyses	
	Crude OR 95% CI	p	Adjusted OR 95% CI	p
Age	1.09 [1.01-1.19]	0.036	1.14 [1.02-1.28]	0.019
BMI	0.93 [0.83-1.04]	0.196	0.91 [0.77-1.08]	0.204
Nulliparity	4.18 [1.66-10.53]	0.003	6.16 [2.13-17.76]	0.002
Smoking	1.08 [0.29-3.36]	0.996	1.65 [0.37-7.22]	0.141
Disease activity*	1.06 [0.40-2.81]	0.911	0.98 [0.21-2.28]	0.753
Corticosteroids**	2.45 [1.05-5.68]	0.039	3.22 [1.09-9.57]	0.038
Biologics**	1.05 [0.11-3.54]	0.589	2.02 [0.70-4.12]	0.194

\* Moderate or severe disease activity at least once during pregnancy. \*\* Use at least once during pregnancy

**Acknowledgements:** The GR2 Cohort is supported by the French Society of Rheumatology, the French Internal Medicine Society, and unrestricted grants from UCB.

**Disclosure of Interests:** SABRINA HAMROUN: None declared, Marion Couderc: None declared, Rene-Marc Flipo: None declared, Laure Gossec: None declared, Christophe Richez Speakers bureau: CR has received consulting/speaker's fees from Abbvie, Amgen, Astra Zeneca, Biogen, BMS, Celltrion, Eli Lilly, Galapagos, GSK, MSD, Novartis, and Pfizer, all unrelated to this manuscript., Rakiba Belkhir: None declared, Aline Frazier-Mironer: None declared, Valerie Devauchelle-Pensec: None declared, Hubert MAROTTE: None declared, Jérémie SELLAM: None declared, Elisabeth Gervais: None declared, Alban Deroux: None declared, Cédric Lukas: None declared, Emmanuelle Derris: None declared, Emmanuel Chatelus: None declared, Nathalie Costedoat-Chalumeau: None declared, Anna Moltó: None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4496

OP0128

### ADHERENCE TO MEDICATIONS DURING PREGNANCY IN SYSTEMIC AUTOIMMUNE DISEASE

D. Zucchi<sup>1</sup>, F. Racca<sup>1</sup>, C. Tani<sup>1</sup>, E. Elefante<sup>1</sup>, C. Stagnaro<sup>1</sup>, L. Carli<sup>1</sup>, V. Signorini<sup>1</sup>, F. Ferro<sup>1</sup>, F. Trentin<sup>1</sup>, S. Gori<sup>1</sup>, M. Mosca<sup>1</sup>. <sup>1</sup>Rheumatology Unit, Department of Clinical and Experimental Medicine, Pisa, Italy

**Background:** Low medication adherence is a well known issue in the management of patients with systemic autoimmune diseases (SAD), little however is known on adherence to medication during pregnancy, especially in these patients with high risk pregnancies.

**Objectives:** This study is aimed at evaluating the level of adherence to medication in pregnant patients with SAD in comparison with non-pregnant patients with SAD, and at identifying determinants of low adherence.